Renin-angiotensin system blockade in diabetic kidney disease: an old pillar that still stands at the core of therapy
Article information
Abstract
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Activation of the renin-angiotensin system (RAS) plays a central role in the pathogenesis of DKD by promoting intraglomerular hypertension, albuminuria, inflammation, oxidative stress, and progressive fibrosis. Angiotensin II-mediated efferent arteriolar constriction increases glomerular capillary pressure, while non-hemodynamic effects, including upregulation of transforming growth factor-β, NADPH oxidase-dependent reactive oxygen species generation, and podocyte apoptosis, contribute to structural kidney injury. Large, randomized trials have consistently demonstrated that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce albuminuria, slow the glomerular filtration rate decline, and delay kidney failure across different stages of DKD. Evidence also supports cardiovascular benefits, including reduced heart failure events, in patients with DKD. A reduction in albuminuria is closely correlated with long-term kidney outcomes, underscoring its role as a mechanistic and therapeutic marker. Concerns regarding safety in advanced chronic kidney disease have been addressed by recent evidence indicating that routine discontinuation of RAS blockade does not improve kidney function and may increase cardiorenal risk. Although newer agents have expanded the therapeutic options, RAS inhibition remains the foundational therapy for DKD. This review summarizes the mechanistic basis, clinical evidence, safety considerations, and contemporary perspectives of RAS blockade in DKD.
Introduction
Diabetic kidney disease (DKD) is the most common cause of chronic kidney disease (CKD) and kidney failure worldwide and is a major contributor to cardiovascular morbidity and mortality in patients with diabetes [1]. The global prevalence of DKD has continued to increase in parallel with the rising burden of type 2 diabetes mellitus, particularly in Asian populations in which early-onset diabetes and metabolic syndrome are increasingly prevalent [1,2]. Clinically, DKD is characterized by persistent albuminuria, progressive decline in the estimated glomerular filtration rate (eGFR), and an elevated risk of cardiovascular disease [3].
Although multifactorial mechanisms contribute to DKD progression, activation of the renin-angiotensin system (RAS) has long been recognized as a central driver of both functional and structural kidney injury [4]. The development of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) marked a pivotal turning point in the management of DKD [5–7]. For more than three decades, RAS blockade has served as the cornerstone of kidney-protective therapy in patients with diabetes and albuminuria [8].
In recent years, the therapeutic landscape of DKD has expanded substantially with the introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 (GLP-1) receptor agonists, leading to the concept of a “four-pillar” strategy for cardiorenal protection [9,10]. Despite these advances, RAS blockade remains the foundational therapy upon which newer disease-modifying agents are layered. A clear understanding of the mechanistic basis, clinical trial evidence, and safety considerations of RAS inhibition is essential for modern management of DKD. In this review, we summarized the pathophysiological rationale, major clinical trial evidence across the spectrum of DKD, cardiovascular implications, and safety considerations of RAS blockade, highlighting its enduring role as a central pillar of therapy.
Pathophysiologic rationale
The activation of the RAS is a central driver of DKD development and progression [11,12]. Hyperglycemia, advanced glycation end products, and intraglomerular hypertension upregulate intrarenal angiotensin II (Ang II) generation independently of systemic RAS activity [13,14]. By binding predominantly via the Ang II type 1 (AT1) receptor, Ang II preferentially constricts the efferent arteriole, leading to increased intraglomerular pressure, glomerular hyperfiltration, and consequent albuminuria [15–17]. In addition, Ang II promotes mesangial cell proliferation, podocyte injury, increased glomerular basement membrane permeability, and expansion of the extracellular matrix (Fig. 1) [18–20].
Pathophysiological mechanisms of RAS activation in diabetic kidney disease.
Chronic hyperglycemia and metabolic stress activate the intrarenal RAS, leading to an increased generation of angiotensin II. Angiotensin II preferentially constricts the efferent arterioles, resulting in elevated intraglomerular pressure and glomerular hyperfiltration, which promote albuminuria and progressive glomerular injury. Beyond hemodynamic effects, angiotensin II stimulates transforming growth factor beta (TGF-β), oxidative stress, and inflammatory signaling pathways, contributing to mesangial expansion, podocyte injury, and tubulointerstitial fibrosis. Angiotensin-converting enzyme (ACE) inhibitors reduce angiotensin II formation and increase bradykinin, whereas angiotensin receptor blockers selectively inhibit angiotensin II type 1 receptor (AT1R) signaling. Through these mechanisms, RAS blockade lowers albuminuria and slows down the decline in the estimated glomerular filtration rate.
RAS, renin-angiotensin system; VEGF, vascular endothelial growth factor.
Beyond hemodynamics, Ang II exerts strong non-hemodynamic effects that are highly relevant to DKD: it stimulates transforming growth factor-β and other profibrotic growth factors [21,22], enhances oxidative stress and NADPH oxidase activity [23,24], and upregulates pro-inflammatory pathways (nuclear factor kappa B, monocyte chemoattractant protein-1, and adhesion molecules) [25,26], thereby accelerating glomerulosclerosis and tubulointerstitial fibrosis. Ang II-induced aldosterone further amplifies inflammation and fibrosis in the tubulointerstitium [27].
These mechanistic insights provide a rationale for pharmacological RAS inhibition as a core disease-modifying strategy in DKD. ACEis reduce Ang II generation and increase bradykinin [28], whereas ARBs selectively block AT1 receptors while preserving AT2 receptor signaling [16,29]. Experimental models and human data have consistently shown that the RAS blockade reduces intraglomerular pressure, lowers albuminuria, attenuates inflammation and fibrosis, and ameliorates structural kidney damage [5,17,30–33].
Therefore, the current Kidney Disease: Improving Global Outcomes (KDIGO) 2022 diabetes and KDIGO 2024 CKD guidelines recommend ACEi or ARB at maximally tolerated doses as first-line antihypertensive and renoprotective therapies in patients with CKD and diabetes with moderately to severely increased albuminuria (A2–A3) [8,34].
Clinical trial evidence across the spectrum of diabetic kidney disease
Prevention of development of diabetic kidney disease
Beyond slowing the progression of established DKD, inhibition of the RAS has also been investigated for its potential to prevent the development of DKD. Early studies on patients with diabetes and normoalbuminuria suggested that ACEis may have delayed the onset of microalbuminuria [35]. In a randomized trial involving normotensive patients with type 1 diabetes, the ACEi enalapril significantly reduced the risk of developing microalbuminuria compared with placebo, indicating that RAS activation contributes to early glomerular injury even before overt kidney disease becomes clinically apparent.
Similar findings were observed in patients with type 2 diabetes. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention study evaluated the effects of olmesartan in patients with type 2 diabetes and normoalbuminuria [36]. Olmesartan significantly delayed the onset of microalbuminuria compared with placebo, although overall kidney function decline was similar between groups. These findings suggest that RAS blockade can modify the early pathogenic pathways that lead to DKD. However, because the absolute risk reduction was modest, and concerns regarding cardiovascular events emerged in some analyses, the routine use of RAS inhibitors solely for the primary prevention of DKD in normoalbuminuric patients remains controversial.
Type 1 diabetes and overt nephropathy
The landmark captopril trial in patients with type 1 diabetes provided the first definitive evidence that RAS blockade offers kidney protection beyond lowering blood pressure (BP) [5]. In patients with insulin-dependent diabetes and established nephropathy, captopril significantly reduced the risk of doubling of serum creatinine, end-stage kidney disease (ESKD), or death compared with placebo, despite similar BP achieved in the comparator arms. Long-term extension data in normotensive patients with type 1 diabetes and nephropathy showed sustained kidney protection over 8 years, supporting the early initiation of ACEi irrespective of baseline BP [37].
These trials established several key mechanistic concepts: 1) RAS blockade slows the GFR decline in DKD; 2) benefits cannot be fully explained by systemic BP reduction; and 3) albuminuria reduction under ACEi therapy correlates with better kidney prognosis, suggesting that albuminuria is both a therapeutic target and a surrogate endpoint.
Type 2 diabetes with microalbuminuria
The progression from microalbuminuria to overt nephropathy is a critical step in type 2 diabetes with CKD, and ARB trials have demonstrated that RAS blockade can delay this transition. In the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria trial, patients with hypertension, type 2 diabetes, and persistent microalbuminuria were randomized to receive irbesartan 150 mg, irbesartan 300 mg, or placebo in addition to conventional therapy [38]. High-dose irbesartan (300 mg) reduced the risk of progression to overt nephropathy by approximately 70% compared with placebo, with a clear dose-response relationship and kidney benefit that exceeded that expected from BP differences alone. Post hoc analyses showed that early and sustained reductions in albuminuria with irbesartan treatment predicted long-term kidney protection, reinforcing the mechanistic link between intraglomerular pressure, albuminuria, and structural kidney injury [39]. Overall, these data support the use of RAS blockade at the microalbuminuric stage as a strategy to prevent or delay overt nephropathy.
Type 2 diabetes with overt nephropathy
Two large outcome trials, Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) and Irbesartan Diabetic Nephropathy Trial (IDNT), firmly established ARBs as renoprotective agents in patients with macroalbuminuria and impaired kidney function. In the RENAAL study, losartan added to conventional antihypertensive therapy reduced the risk of the composite endpoint (doubling of serum creatinine, ESKD, or death) by 16% versus placebo and lowered the risk of ESKD by approximately 28% in patients with type 2 diabetes and nephropathy [6]. Losartan also slowed the rate of eGFR decline and reduced albuminuria, further supporting a BP-independent mechanism.
The IDNT compared irbesartan, amlodipine, and placebo in patients with hypertension, type 2 diabetes, and proteinuric nephropathy [7]. Irbesartan reduced the risk of the primary kidney composite outcome (doubling of serum creatinine, ESKD, or death) by approximately 20% compared with placebo and by 24% compared with amlodipine, despite similar BP levels in the active arms. Subsequent analyses confirmed that both achieved BP and ARB allocation independently and additively predicted kidney outcomes, emphasizing the dual importance of tight BP control and specific RAS blockade [40].
These pivotal trials are summarized in Table 1, which outlines the populations, interventions, and kidney outcomes across major ACEi/ARB studies. Meta-analyses and reviews integrating these and other ACEi/ARB trials have consistently shown that RAS blockade in macroalbuminuric type 2 DKD reduces the risk of GFR decline, ESKD, and death, with the magnitude of the benefit closely related to baseline albuminuria and its degree of reduction [9,41].
Mechanism–outcome link: reduction of albuminuria and early estimated glomerular filtration rate dip
Across studies, two mechanistic markers repeatedly link RAS blockade to improved renal outcomes:
1. Reduction in albuminuria: In ACEi/ARB trials in both type 1 and type 2 DKD, on-treatment albuminuria reduction has been a strong, graded predictor of slower GFR decline and lower risk of ESKD, independent of BP [39,40]. This supports the concept that lowering the intraglomerular pressure and restoring glomerular barrier integrity directly translates into structural kidney protection.
2. Initial hemodynamic “dip” in eGFR: A modest acute decline in eGFR after initiating RAS blockade reflects efferent arteriolar vasodilation and reduced intraglomerular pressure. Observational analyses suggest that patients with a small early eGFR dip but subsequent stabilization often have better long-term outcomes than those without such a decrease or those with a large, persistent decline, which is consistent with a hemodynamic mechanism of benefit [42].
These mechanistic relationships underlie the current practice of targeting meaningful albuminuria reduction (often ≥30% to 50% from baseline) as a therapeutic goal in the treatment of DKD, emphasizing that the therapeutic effect of RAS blockade is mechanistically mediated through reduction of intraglomerular hypertension and restoration of the filtration barrier. In particular, data from a nationwide Korean cohort have demonstrated that albuminuria is associated with an increased risk of early-onset type 2 diabetes, supporting its role as an early marker of systemic metabolic and renal vulnerability in Asian populations [43]. Table 2 integrates these hemodynamic and non-hemodynamic mechanisms and their clinical implications.
Mechanistic pathways and clinical implications of renin-angiotensin system blockade in diabetic kidney disease
These mechanistic relationships highlight how the hemodynamic effects of RAS blockade translate into meaningful kidney protection. However, the clinical impact of RAS inhibition in DKD extends beyond kidney outcomes. Because patients with DKD are at a particularly high risk of cardiovascular complications, therapies targeting intrarenal hemodynamics and systemic vascular pathways may also influence cardiovascular outcomes.
Cardiovascular outcomes associated with renin-angiotensin system blockade in diabetic kidney disease
In addition to their established effects on albuminuria reduction and slowing kidney function decline, RAS inhibitors exert important cardiovascular protective effects in patients with DKD. Individuals with DKD have a markedly increased risk of cardiovascular morbidity and mortality, and cardiovascular events often precede the progression to kidney failure [44]. Ang II contributes to multiple pathophysiological processes involved in cardiovascular disease, including endothelial dysfunction, vascular inflammation, oxidative stress, myocardial fibrosis, and left ventricular remodeling [45]. Therefore, RAS blockade may have cardioprotective effects beyond BP reduction.
Evidence supporting the cardiovascular benefits of RAS inhibition in DKD has been obtained from several large, randomized trials. In the RENAAL study, treatment with the ARB losartan significantly reduced the risk of hospitalization for heart failure compared with placebo in patients with type 2 diabetes and nephropathy [6]. Similarly, analyses from the IDNT trial demonstrated that irbesartan reduced the risk of heart failure events compared with amlodipine or placebo [7]. Beyond these disease-specific trials, broader cardiovascular outcome studies such as the HOPE trial showed that ACE inhibition with ramipril significantly lowered the risk of myocardial infarction, stroke, and cardiovascular death among high-risk patients with diabetes [46]. These cardiovascular benefits further support the role of RAS blockade as the foundational therapy for DKD, upon which newer cardiorenal protective agents are layered in contemporary treatment strategies.
Safety and limitations of renin-angiotensin system blockade
Despite its clear benefits, the inhibition of RAS has several important safety considerations. ACEi/ARB therapy may cause hyperkalemia, acute increases in serum creatinine, and symptomatic hypotension, risks that are accentuated in advanced CKD, with volume depletion, or when combined with other nephrotoxic agents. Therefore, KDIGO recommends monitoring BP, serum creatinine, and potassium within 2–4 weeks after initiation or dose escalation and continuing therapy unless creatinine rises by >30% or hyperkalemia cannot be controlled [8].
Concerns have long existed regarding the safety of continuing RAS inhibitors in advanced CKD because of the risks of hyperkalemia and an acute decline in eGFR. The randomized STOP-ACEi trial directly addressed this issue by comparing the continuation versus discontinuation of ACEi/ARB therapy in patients with progressive stage 4–5 CKD [47]. After 3 years, no improvement was observed in eGFR with withdrawal of RAS blockade (12.6 mL/min/1.73 m2 vs. 13.3 mL/min/1.73 m2; difference, −0.7; 95% confidence interval [CI], −2.5 to 1.0), and rates of ESKD or initiation of kidney replacement therapy were higher in the discontinuation group (62% vs. 56%; hazard ratio, 1.28; 95% CI, 0.99–1.65). In another large population-based cohort study including more than 10,000 patients with type 2 diabetes and advanced CKD (eGFR <30 mL/min/1.73 m2), discontinuation of ACEis or ARBs was associated with a significantly higher risk of major adverse cardiovascular events, heart failure, and progression to ESKD than continued therapy, while the risk of all-cause mortality remained neutral [48]. These data indicate that routine withdrawal of RAS blockade is not beneficial in advanced DKD, supporting the continuation of a maximally tolerated single-agent ACEi or ARB with careful monitoring.
Attempts to intensify RAS blockade beyond a single-agent ACEi or ARB have been disappointing or harmful. Dual ACEi/ARB therapy in high-risk diabetes populations (ONTARGET and related studies) did not improve cardiovascular or kidney outcomes and was associated with an increased risk of hyperkalemia, hypotension, and kidney function decline [49,50]. Similarly, the addition of the direct renin inhibitor aliskiren to ACEi/ARB in type 2 diabetes (ALTITUDE) failed to improve cardiorenal outcomes and increased adverse events, leading to early trial termination and subsequent regulatory warnings [51]. Based on these data, contemporary guidelines explicitly recommend avoiding any combination of ACEi, ARB, and direct renin inhibitor therapy in patients with CKD, with or without diabetes [8].
Importantly, despite clear renoprotective and cardiovascular benefits, a consistent reduction in all-cause mortality with RAS blockade has not been demonstrated in DKD-specific trials. In landmark studies such as RENAAL and IDNT, ARB therapy significantly reduced kidney endpoints but did not confer a statistically significant survival benefit [6,7]. This may reflect competing risks in advanced CKD populations or the multifactorial determinants of mortality in diabetes [52]. In contrast, evidence from broader high-risk populations suggests that RAS inhibition may improve survival. In the HOPE trial, ACE inhibition with ramipril significantly reduced all-cause mortality and major cardiovascular events in patients with diabetes and other cardiovascular risk factors [46]. These findings suggest that the impact of RAS blockade on mortality may be context-dependent.
Finally, even with optimized RAS blockade, a substantial residual renal risk remains, especially in patients with advanced DKD or persistent heavy albuminuria. This residual risk has provided the rationale for the “four-pillar” approach—adding SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists on top of the maximally tolerated ACEi/ARB therapy to more comprehensively address hyperfiltration, metabolic stress, inflammation, and fibrosis.
Summary
RAS blockade with ACEis or ARBs remains the foundational disease-modifying therapy for DKD. By targeting both intrarenal hemodynamic abnormalities and multiple non-hemodynamic pathways, including inflammation, oxidative stress, and fibrosis, RAS inhibition reduces albuminuria, slows the decline in kidney function, and lowers the risk of progression to ESKD in both type 1 and type 2 diabetes. In addition, RAS blockade provides important cardiovascular protection, reflecting the shared pathophysiological mechanisms linking kidney and cardiovascular injuries in diabetes.
Despite the emergence of newer therapeutic agents including SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists, RAS inhibition continues to serve as an essential therapeutic platform for contemporary multidrug strategies. Future treatment paradigms will likely rely on optimized combination therapies built upon maximally tolerated RAS blockade to achieve comprehensive cardiorenal protection in patients with DKD.
Notes
Conflicts of interest
Tae-Hyun Yoo is the Editor-in-Chief of Kidney Research and Clinical Practice and was not involved in the review process of this article. All authors have no other conflicts of interest to declare.
Acknowledgments
MID (Medical Illustration & Design), a member of the Medical Research Support Services of Yonsei University College of Medicine, provided excellent support with medical illustration.
Data sharing statement
The data presented in this study are available from the corresponding author upon reasonable request.
Authors’ contributions
Conceptualization, Investigation: DHK
Supervision: THY
Writing–original draft: DHK
Writing–review & editing: THY
All authors read and approved the final manuscript.
